Business
Respiri (ASX:RSH) share price on watch following FDA approval
The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app.
About Respiri
Respiri is a software-as-a-service (SaaS) company supporting asthma patients to monitor and manage their asthma. The company views that asthma is often under-diagnosed and under-treated, creating a substantial burden to sufferers and their families.
Respiri has created an eHealth SaaS platform, ‘Wheezo’, that uses a device and app to measure, record and monitor asthma symptoms. The device records breath sounds over 30 seconds to be analysed in…
-
General22 hours agoChina was the big disruptor in our region. Now the US is determined to take that title
-
General22 hours agoSpaceX to invest $3 billion in Musk’s xAI startup
-
General19 hours agoWimbledon men’s final, Jannik Sinner vs Carlos Alcaraz live updates — blog, scores and stats
-
General10 hours agoJannik Sinner reveals secret Wimbledon bet that could keep Darren Cahill in his team